GRDN trades 3.1% above Wall Street's consensus target of $41.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes GRDN achieves its forward estimates and maintains a stable P/E multiple of 33.6x. This scenario reflects the blended consensus of 4 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 28, 2026, Guardian Pharmacy Services, Inc. (GRDN) has a Wall Street consensus price target of $41.00, based on estimates from 4 covering analysts. With the stock currently trading at $42.31, this represents a potential downside of -3.1%. The company has a market capitalization of $2.68B.
Analyst price targets range from a low of $36.00 to a high of $47.00, representing a 27% spread in expectations. The median target of $40.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 4 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, GRDN trades at a trailing P/E of 54.2x and forward P/E of 33.6x. The forward PEG ratio of 1.79 indicates reasonable valuation for growth. Analysts expect EPS to grow +51.2% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $32.86, with bear and bull scenarios of $20.70 and $43.29 respectively. Model confidence stands at 51/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
OMCLOmnicell, Inc. | $1.8B | $40.13 | $57.20 | +42.5% | Hold | 20.7x | 19 |
PINCPremier, Inc. | $2.3B | $28.26 | $33.15 | +17.3% | Hold | 20.8x | 31 |
CVSCVS Health Corporation | $133.1B | $104.34 | $103.64 | -0.7% | Buy | 14.1x | 41 |
CCRNCross Country Healthcare, Inc. | $427M | $13.22 | $12.50 | -5.4% | Hold | 142.9x | 14 |
MCKMcKesson Corporation | $91.8B | $763.51 | $994.86 | +30.3% | Buy | 17.3x | 31 |
CAHCardinal Health, Inc. | $56.0B | $237.92 | $253.38 | +6.5% | Buy | 22.1x | 33 |
VEEVVeeva Systems Inc. | $27.8B | $171.36 | $235.38 | +37.4% | Buy | 18.9x | 43 |
ENSGThe Ensign Group, Inc. | $9.5B | $163.05 | $222.33 | +36.4% | Buy | 21.6x | 13 |
SEMSelect Medical Holdings Corporation | $2.1B | $16.54 | $17.75 | +7.3% | Hold | 13.6x | 14 |
ADUSAddus HomeCare Corporation | $1.8B | $96.95 | $122.00 | +25.8% | Buy | 13.9x | 16 |
Quick answers to the most common questions about buying GRDN stock.
Wall Street's consensus price target for GRDN is $41, -3.1% from its current price of $42.31. The below-market target from 4 analysts suggests limited near-term appreciation.
GRDN has a consensus rating of "Buy" based on 4 Wall Street analysts. The rating breakdown is predominantly bullish, with 4 Buy/Strong Buy ratings. The consensus 12-month price target of $41 implies -3.1% downside from current levels.
GRDN trades at a forward P/E of 33.5794x, representing a moderate valuation. With analysts targeting $41 (-3.1% implied move), the stock appears close to fair value.
The most bullish Wall Street analyst has a price target of $47 for GRDN, while the most conservative target is $36. The consensus of $41 represents the median expectation. Our quantitative valuation model projects a bull case target of $43 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
GRDN is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month GRDN stock forecast based on 4 Wall Street analysts shows a consensus price target of $41, with estimates ranging from $36 (bear case) to $47 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $33, with bear/bull scenarios of $21/$43.
Our quantitative valuation model calculates GRDN's fair value at $33 (base case), with a bear case of $21 and bull case of $43. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 51/100.
GRDN trades at a forward P/E ratio of 33.6x based on next-twelve-months earnings estimates compared to a trailing P/E of 54.2x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Analysts are cautious on GRDN, with 0 Sell ratings and a price target of $41 (-3.1% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
GRDN analyst price targets range from $36 to $47, a 27% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $41 consensus represents the middle ground. Our model's $21-$43 range provides an independent fundamental perspective.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.